HER2-antigen specific cancer immunotherapeutic
Alternative Names: dHER2+AS15; dHER2+AS15 ASCI; HER2 ASCI; Recombinant HER2 protein - GSKLatest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Cancer vaccines; Recombinant proteins
- Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 04 Dec 2006 Phase-II clinical trials in Breast cancer in Australia (IV-injection)
- 04 Dec 2006 Phase-II clinical trials in Breast cancer in Belgium (IV-injection)
- 04 Dec 2006 Phase-II clinical trials in Breast cancer in France (IV-injection)